Antiretroviral pharmacokinetic profile: a review of sex differences.
about
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allNon-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityInfluence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in IndiaSex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseasesImpact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study.Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The NetherlandsAtazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.Gender-based personalized pharmacotherapy: a systematic review.Adherence to antiretroviral therapy (ART) during the early months of treatment in rural Zambia: influence of demographic characteristics and social surroundings of patientsDifferences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status.Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIVCaring for women living with HIV: gaps in the evidence.Considerations for the antiretroviral management of women in 2008.A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso.Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study.Sex-specific differences in treatment outcomes for patients with HIV and AIDS.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Renal histoarchitectural changes in nevirapine therapy: possible role of kolaviron and vitamin C in an experimental animal model.The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.A new linear model-based approach for inferences about the mean area under the curve.Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort.Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.Precision medicine for HIV: where are we?Gender and mental health aspects of living with HIV disease and its longer-term outcomes for UK heterosexual patients.Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q24609011-497334EE-27C3-43D4-92B3-387FE37A0994Q24628212-7D3E4BCC-C836-4094-862E-40BEE0523A15Q28540682-5C44B85F-D120-4D0C-9A07-7430DCB2B415Q33997400-A2171E3B-E81E-4F25-8CF5-EA406BD86E4BQ34472398-1C7D10B6-870E-4D41-9565-635A0BB0FEEFQ34474961-4782941B-63C8-4200-A8AC-C43F7F5E27ACQ34754376-92C03FA8-56E9-405E-924E-4E64B0865681Q35010207-284B396D-AFBC-4FD8-9F09-E64CA8819951Q35079510-1D95E427-A318-4290-A245-272D3397C084Q35689226-85BC8C1F-D9FD-4C52-BDFF-36296021A005Q35867025-0B7C0BC2-6C77-44B0-BBDD-C2F1FDB8A209Q35944787-0F70AF02-EC0A-44F4-8B46-FC805CDE2B15Q36206201-8A18EA0A-2597-4250-8EA9-A5FB2646502EQ36335289-D0B1E86C-56E5-4CF4-AEC9-F0B3806A3FA9Q36690309-48B45CD4-EF60-41E9-A0AA-7E1084FACE86Q36730274-0602C7C3-2F73-4D77-8BD6-017476433FD9Q36840809-33031DAE-066B-4FE0-9CD1-456302906D9AQ37212049-E2FF84B9-6B3C-43D2-B8F8-E97ABFE6F4BAQ37346125-7D0D0615-6B0B-49E2-AD3D-B6942BCFEC59Q37471061-C0EBF9C2-6448-492C-A774-D7F62FE576E3Q37491656-A50F9F29-E571-467E-950F-12AC38E2E1A0Q37691625-533A63EC-BD07-4DAB-AC74-341DF5B64704Q37712960-7F726515-78C0-4F10-8FE8-E750BA90C85EQ37866298-4A39202D-D3A5-42A0-9BBB-8E7BB4B3218BQ38418210-BCF26B45-8251-476D-9BF8-542D3153C8CCQ40129396-14209FF0-F3FE-4F7F-AB33-6C476CEF657AQ40694902-85953135-1C97-4C65-BA5F-289BBB835145Q42262966-75AC383A-5D4B-4362-A358-B90014601208Q43846085-B45071B0-772E-43A8-A1AD-A6A51F830C40Q44626162-B8734807-A9CE-4908-B7F8-1887F7AC7DE9Q46118142-A61A6656-35A7-4248-B739-02F306A8F339Q46544848-040FF595-8A81-45C9-9037-0BB3F43AB052Q47359813-29FA0051-A2DB-41B9-8295-0068C4D2948DQ47569821-313A4999-47A3-40C1-9027-A7765F057FC9Q48450425-3804EB86-5358-4A3D-9BF9-0AED37CE9CD5Q51202282-634BEDA5-C11A-4DAC-AB52-939A1D7E5D9AQ57180790-7810D3DF-C62E-4E5F-B6C5-A9105821316B
P2860
Antiretroviral pharmacokinetic profile: a review of sex differences.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antiretroviral pharmacokinetic profile: a review of sex differences.
@en
type
label
Antiretroviral pharmacokinetic profile: a review of sex differences.
@en
prefLabel
Antiretroviral pharmacokinetic profile: a review of sex differences.
@en
P2093
P1433
P1476
Antiretroviral pharmacokinetic profile: a review of sex differences.
@en
P2093
Ighovwerha Ofotokun
Jane E Hitti
Susan K Chuck
P304
P356
10.1016/S1550-8579(07)80025-8
P577
2007-06-01T00:00:00Z